China (Mainland)
manufacture Ziconotide Acetate CAS NO.107452-89-1
- FOB Price: USD: 10.00-20.00 /Gram Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
Top Grade(1-10)Gram Top Grade(10-50)Gram
- Product Details
Keywords
- Ziconotide Acetate powder
- Ziconotide Acetate raw powder
- Ziconotide Acetate Injection
Quick Details
- ProName: manufacture Ziconotide Acetate
- CasNo: 107452-89-1
- Molecular Formula: C102H172N36O32S7
- Appearance: White to off white powder
- Application: Pharmaceutical
- DeliveryTime: Within 7 working days
- PackAge: plastic tube/vials
- Port: Shanghai
- ProductionCapacity: 1000 Gram/Week
- Purity: ≥98%
- Storage: Store in a cool dry place and keep awa...
- Transportation: EMS,TNT,DHL
- LimitNum: 10 Gram
- Moisture Content: 0
- Impurity: 0
- Certification: GMP
- Molecular: 1031.17
- Specification: iu mg g kg
- Customized: Customized
Superiority
Superiority
1.As a professional production leading factory & lab in China in pharmaceutical area of 15 years, our market to USA, Australia, Middle East, Germany, Spain, UK, and so on other country. What’s more, good feedback from our customers. We had Established long friendly relations of cooperation.
2.High quality, best price, firstclass service, high successful delivery rate.
3.We have stock, so we can delivery quickly at the very day when receive the payment.
4.We will never sell, solicit,or give your information to any third parties. All transactions are confidential.Your satisfaction is guaranteed,as long as you have dissatisfaction,we will show our biggest sincerity and patience to solve problems.
5.We have the special way can ship 50 grams to 50kg products at a time. We can offer the melting powder into liquid service.And ship the liquid in the special bottles. According to your request and the quantity what you buy, we have several packaging methods for your choice. safety and quick shipping to you.
6.We can do ,TT and Money Gram wire transfer payment term.
Details
Lab Supply Pharmaceutical Intermediate Powder Peptide Ziconotide Acetate 107452-89-1
Description
Ziconotide is a powerful analgesic drug that has a unique mechanism of action involving potent and selective block of N-type calcium channels, which control neurotransmission at many synapses. The analgesic efficacy of ziconotide likely results from its ability to interrupt pain signaling at the level of the spinal cord. Ziconotide is a peptidic drug and has been approved for the treatment of severe chronic pain in patients only when administered by the intrathecal route. Importantly, prolonged administration of ziconotide does not lead to the development of addiction or tolerance. The current review discusses the various studies that have addressed the in vitro biochemical and electrophysiological actions of ziconotide as well as the numerous pre-clinical studies that were conducted to elucidate its antinociceptive mechanism of action in animals. In addition, this review considers the pivotal Phase 3 (and other) clinical trials that were conducted in support of ziconotide's approval for the treatment of severe chronic pain and tries to offer some insights regarding the future discovery and development of newer analgesic drugs that would act by a similar mechanism to ziconotide but which might offer improved safety, tolerability and ease of use.
Ziconotide's pharmacological effects have been investigated extensively in pre-clinical in vivo and in vitro models. Briefly, intrathecal ziconotide is a powerful antinociceptive drug in several animal models of chronic pain and it appears to have a completely novel mechanism of action that involves potent and selective block of pre-synaptic neuronal N-type calcium channels in the spinal cord. In fact, it is the only selective N-type channel blocker that is currently approved for clinical use. Evidence suggests that ziconotide delivers its antinociceptive efficacy by reducing the release of pronociceptive neurotransmitters in the dorsal horn of the spinal cord, thereby inhibiting pain signal transmission. Intrathecal ziconotide's clinical efficacy is consistent with the hypothesis that spinal N-type calcium channels are key regulators of nociceptive signaling in humans, although it is fair to say that its precise analgesic mechanism in humans remains unconfirmed at this time.
Ziconotide: pre-clinical in vivo studies
Ziconotide has been described as a potent and long-lasting antinociceptive drug when administered by the intrathecal route. Experimental evidence of ziconotide's antinociceptive properties was first obtained in the early 1990s and since then extensive studies have been conducted to characterize its effects in multiple animal models of pain. It is also important to note that ziconotide can be efficacious under a variety of intrathecal dosing regimens, including single bolus injection and acute or chronic continuous infusion. Despite its potent efficacy, the therapeutic index of spinal ziconotide tends to be low and often its antinociceptive effects in animals are accompanied by motor deficits at higher doses. Although ziconotide does not easily cross the blood brain barrier in normal animals, it may cause hypotension if it enters the systemic circulation (Bowersox et al 1992; Wright et al 2000; Takahara et al 2002). This effect on blood pressure appears to be mediated at least partially by inhibition of sympathetic neurotransmission, probably as a result of N-type calcium channel blockade in sympathetic nerve terminals (Wang et al 1998).
Ziconotide: clinical studies
The development path to regulatory approval of intrathecal ziconotide involved three large randomized, double-blind, placebo-controlled Phase 3 clinical trials that established the safety and analgesic efficacy of this drug in more than 600 patients (see Table 4A). All of the patients in these trials were suffering from severe chronic pain of malignant and/or non-malignant origins (Staats et al 2004; Rauck et al 2006; Wallace et al 2006) and in order for them to be accepted into the trials, it was necessary that their pain was inadequately controlled by other analgesic drugs, including opioids. These clinical trials evaluated the analgesic efficacy of ziconotide under chronic dosing paradigms (up to 3 weeks) in order to determine the potential for this drug to develop tolerance. In addition to these pivotal trials, a smaller placebo-controlled clinical trial demonstrated analgesic efficacy of ziconotide in a post-surgical setting and a number of open-label studies showed that ziconotide can be an effective therapy in the treatment of neuropathic pain.
Future prospects and concluding remarks
Ziconotide represents a great achievement for current pain therapy but despite its potent analgesic efficacy there remains significant opportunity for improvement. The opportunity derives primarily from the peptidic nature of the drug and its requirement for intrathecal administration in order to yield analgesic efficacy with reduced potential for systemic and central nervous system side-effects. Consequently, drug discovery researchers are considering various approaches to identify and develop novel orally active, N-type calcium channel-selective blockers that have the potential to be superior to ziconotide.
Our process:
The quality control process
1)Purchasing
Thorough market research, understand the price of raw materials and performance.To the procurement source to understand fully, and fully guarantee the quality of the procurement of raw materials.
2) Inspection
Four steps: sampling, sample pretreatment, measuring and data processing.
3) Producing
a)Each operator must do self-inspection of producs and make the corresponding inspection records.
b)Full-time inspectors through check the operator self-inspection, and review and sign in the corresponding record. Full-time inspection is responsible for inspection of finished product, and make the finished product incoming inspection records.
4) Before selling
Test result can be provided before selling.
Third-party detection institution is allowed if you are not satisfied with test results.
Our advantages:
1. Quality:
Our company is a professional production of hormone intermediates for many years, our products have exported to Germany,Spain, UK, USA, Australia, Middle East, and so on other country, and we have got very good feedback from our customers, you can trust us.
And we are the manufactory, so no problem for us to control the quality.
2.Payment method: ,TT.
3.Service: Best service with after-sales service to all clients.
4.Delivery:
Sample Order :Package will be shipped with 3days after payment. We can send it via UP, EMS, HK Air Post, DHL or othermethod. We have a professional and stable logistics, and we can deliver the package smoothly around 3 to 5 days.
Description
| Ziconotide acetate Basic information |
| Product Name: | Ziconotide acetate |
| Synonyms: | OMEGA-CONOTOXIN MVIIA;OMEGA-CGTX MVII A;ZICONOTIDE ACETATE;snx111;H-CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2;H-CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2 (DISULFIDE BRIDGE: 1-16, 8-20, AND 15-25);CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2;CKGKGAKCSRLMYDCCTGSCRSGKC-NH2 (DISULFIDE BRIDGE: 1-16,8-20, AND 15-25) |
| CAS: | 107452-89-1 |
| MF: | C102H172N36O32S7 |
| MW: | 2639.13 |
| EINECS: | |
| Product Categories: | Peptide |
| Mol File: | 107452-89-1.mol |
Ziconotide is a powerful analgesic drug that has a unique mechanism of action involving potent and selective block of N-type calcium channels, which control neurotransmission at many synapses. The analgesic efficacy of ziconotide likely results from its ability to interrupt pain signaling at the level of the spinal cord. Ziconotide is a peptidic drug and has been approved for the treatment of severe chronic pain in patients only when administered by the intrathecal route. Importantly, prolonged administration of ziconotide does not lead to the development of addiction or tolerance. The current review discusses the various studies that have addressed the in vitro biochemical and electrophysiological actions of ziconotide as well as the numerous pre-clinical studies that were conducted to elucidate its antinociceptive mechanism of action in animals. In addition, this review considers the pivotal Phase 3 (and other) clinical trials that were conducted in support of ziconotide's approval for the treatment of severe chronic pain and tries to offer some insights regarding the future discovery and development of newer analgesic drugs that would act by a similar mechanism to ziconotide but which might offer improved safety, tolerability and ease of use.
Ziconotide's pharmacological effects have been investigated extensively in pre-clinical in vivo and in vitro models. Briefly, intrathecal ziconotide is a powerful antinociceptive drug in several animal models of chronic pain and it appears to have a completely novel mechanism of action that involves potent and selective block of pre-synaptic neuronal N-type calcium channels in the spinal cord. In fact, it is the only selective N-type channel blocker that is currently approved for clinical use. Evidence suggests that ziconotide delivers its antinociceptive efficacy by reducing the release of pronociceptive neurotransmitters in the dorsal horn of the spinal cord, thereby inhibiting pain signal transmission. Intrathecal ziconotide's clinical efficacy is consistent with the hypothesis that spinal N-type calcium channels are key regulators of nociceptive signaling in humans, although it is fair to say that its precise analgesic mechanism in humans remains unconfirmed at this time.
Ziconotide: pre-clinical in vivo studies
Ziconotide has been described as a potent and long-lasting antinociceptive drug when administered by the intrathecal route. Experimental evidence of ziconotide's antinociceptive properties was first obtained in the early 1990s and since then extensive studies have been conducted to characterize its effects in multiple animal models of pain. It is also important to note that ziconotide can be efficacious under a variety of intrathecal dosing regimens, including single bolus injection and acute or chronic continuous infusion. Despite its potent efficacy, the therapeutic index of spinal ziconotide tends to be low and often its antinociceptive effects in animals are accompanied by motor deficits at higher doses. Although ziconotide does not easily cross the blood brain barrier in normal animals, it may cause hypotension if it enters the systemic circulation (Bowersox et al 1992; Wright et al 2000; Takahara et al 2002). This effect on blood pressure appears to be mediated at least partially by inhibition of sympathetic neurotransmission, probably as a result of N-type calcium channel blockade in sympathetic nerve terminals (Wang et al 1998).
Ziconotide: clinical studies
The development path to regulatory approval of intrathecal ziconotide involved three large randomized, double-blind, placebo-controlled Phase 3 clinical trials that established the safety and analgesic efficacy of this drug in more than 600 patients (see Table 4A). All of the patients in these trials were suffering from severe chronic pain of malignant and/or non-malignant origins (Staats et al 2004; Rauck et al 2006; Wallace et al 2006) and in order for them to be accepted into the trials, it was necessary that their pain was inadequately controlled by other analgesic drugs, including opioids. These clinical trials evaluated the analgesic efficacy of ziconotide under chronic dosing paradigms (up to 3 weeks) in order to determine the potential for this drug to develop tolerance. In addition to these pivotal trials, a smaller placebo-controlled clinical trial demonstrated analgesic efficacy of ziconotide in a post-surgical setting and a number of open-label studies showed that ziconotide can be an effective therapy in the treatment of neuropathic pain.
Future prospects and concluding remarks
Ziconotide represents a great achievement for current pain therapy but despite its potent analgesic efficacy there remains significant opportunity for improvement. The opportunity derives primarily from the peptidic nature of the drug and its requirement for intrathecal administration in order to yield analgesic efficacy with reduced potential for systemic and central nervous system side-effects. Consequently, drug discovery researchers are considering various approaches to identify and develop novel orally active, N-type calcium channel-selective blockers that have the potential to be superior to ziconotide.
Our process:
The quality control process
1)Purchasing
Thorough market research, understand the price of raw materials and performance.To the procurement source to understand fully, and fully guarantee the quality of the procurement of raw materials.
2) Inspection
Four steps: sampling, sample pretreatment, measuring and data processing.
3) Producing
a)Each operator must do self-inspection of producs and make the corresponding inspection records.
b)Full-time inspectors through check the operator self-inspection, and review and sign in the corresponding record. Full-time inspection is responsible for inspection of finished product, and make the finished product incoming inspection records.
4) Before selling
Test result can be provided before selling.
Third-party detection institution is allowed if you are not satisfied with test results.
Our advantages:
1. Quality:
Our company is a professional production of hormone intermediates for many years, our products have exported to Germany,Spain, UK, USA, Australia, Middle East, and so on other country, and we have got very good feedback from our customers, you can trust us.
And we are the manufactory, so no problem for us to control the quality.
2.Payment method: ,TT.
3.Service: Best service with after-sales service to all clients.
4.Delivery:
Sample Order :Package will be shipped with 3days after payment. We can send it via UP, EMS, HK Air Post, DHL or othermethod. We have a professional and stable logistics, and we can deliver the package smoothly around 3 to 5 days.